Tend to disagree because a billion dollar drug prior to approval can trade at a $400 million market cap. Hence ~ 40 cents. They need to make the case for the platform and the other RAs. And to have real revenue projections. I hate to be negative but it is in management’s hands.
Agree Once timeline goes from NWBO’s control to RAs control after submission , it may generate more interest . It’s difficult to have any level of confidence as long as timeline is in NWBO’s hand .